Incidence and Outcomes of COVID-19 in People With CKD: A Systematic Review and Meta-analysis
Edmund Y.M. Chung,Suetonia C. Palmer,Patrizia Natale,Anoushka Krishnan,Tess E. Cooper,Valeria M. Saglimbene,Marinella Ruospo,Eric Au,Sumedh Jayanti,Amy Liang,Danny Jia Jie Deng,Juanita Chui,Gail Y. Higgins,Allison Tong,Germaine Wong,Armando Teixeira-Pinto,Elisabeth M. Hodson,Jonathan C. Craig,Giovanni F.M. Strippoli
DOI: https://doi.org/10.1053/j.ajkd.2021.07.003
IF: 11.072
2021-12-01
American Journal of Kidney Diseases
Abstract:RATIONALE & OBJECTIVE: <AbstractText Label="RATIONALE &amp; OBJECTIVE">Coronavirus disease 2019 (COVID-19) disproportionately affects people with chronic diseases such as chronic kidney disease (CKD). We assessed the incidence and outcomes of COVID-19 in people with CKD.</AbstractText>STUDY DESIGN: <AbstractText Label="STUDY DESIGN">Systematic review and meta-analysis by searching MEDLINE, EMBASE, and PubMed through February 2021.</AbstractText>SETTING & STUDY POPULATIONS: <AbstractText Label="SETTING &amp; STUDY POPULATIONS">People with CKD with or without COVID-19.</AbstractText>SELECTION CRITERIA FOR STUDIES: <AbstractText Label="SELECTION CRITERIA FOR STUDIES">Cohort and case-control studies.</AbstractText>DATA EXTRACTION: <AbstractText Label="DATA EXTRACTION">Incidences of COVID-19, death, respiratory failure, dyspnea, recovery, intensive care admission, hospital admission, need for supplemental oxygen, hospital discharge, sepsis, short-term dialysis, acute kidney injury, and fatigue.</AbstractText>ANALYTICAL APPROACH: <AbstractText Label="ANALYTICAL APPROACH">Random-effects meta-analysis and evidence certainty adjudicated using an adapted version of GRADE (Grading of Recommendations Assessment, Development and Evaluation).</AbstractText>RESULTS: <AbstractText Label="RESULTS">348 studies (382,407 participants with COVID-19 and CKD; 1,139,979 total participants with CKD) were included. Based on low-certainty evidence, the incidence of COVID-19 was higher in people with CKD treated with dialysis (105 per 10,000 person-weeks; 95% CI, 91-120; 95% prediction interval [PrI], 25-235; 59 studies; 468,233 participants) than in those with CKD not requiring kidney replacement therapy (16 per 10,000 person-weeks; 95% CI, 4-33; 95% PrI, 0-92; 5 studies; 70,683 participants) or in kidney or pancreas/kidney transplant recipients (23 per 10,000 person-weeks; 95% CI, 18-30; 95% PrI, 2-67; 29 studies; 120,281 participants). Based on low-certainty evidence, the incidence of death in people with CKD and COVID-19 was 32 per 1,000 person-weeks (95% CI, 30-35; 95% PrI, 4-81; 229 studies; 70,922 participants), which may be higher than in people with CKD without COVID-19 (incidence rate ratio, 10.26; 95% CI, 6.78-15.53; 95% PrI, 2.62-40.15; 4 studies; 18,347 participants).</AbstractText>LIMITATIONS: <AbstractText Label="LIMITATIONS">Analyses were generally based on low-certainty evidence. Few studies reported outcomes in people with CKD without COVID-19 to calculate the excess risk attributable to COVID-19, and potential confounders were not adjusted for in most studies.</AbstractText>CONCLUSIONS: <AbstractText Label="CONCLUSIONS">The incidence of COVID-19 may be higher in people receiving maintenance dialysis than in those with CKD not requiring kidney replacement therapy or those who are kidney or pancreas/kidney transplant recipients. People with CKD and COVID-19 may have a higher incidence of death than people with CKD without COVID-19.</AbstractText>
urology & nephrology